Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Brii Biosciences Limited ( (HK:2137) ).
Brii Biosciences has initiated arbitration proceedings in the United States against its collaboration partner Vir Biotechnology over alleged breaches of a 2018 Collaboration, Option, and License Agreement and a 2024 letter agreement governing the elebsiran hepatitis B siRNA program. The company seeks specific performance to transfer manufacturing responsibilities for elebsiran from Vir to Brii or its contractors, as well as damages including alleged lost profits and invested amounts, while cautioning investors that the arbitration is at an early stage and its financial impact cannot yet be assessed.
The most recent analyst rating on (HK:2137) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.
More about Brii Biosciences Limited
Brii Biosciences Limited is a Cayman Islands–incorporated biotech company listed in Hong Kong, focused on developing and commercializing innovative therapies, including antiviral candidates such as small interfering RNA (siRNA) treatments targeting hepatitis B virus, with operations conducted through its subsidiary Brii Biosciences Offshore Limited.
Average Trading Volume: 1,078,680
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.02B
See more insights into 2137 stock on TipRanks’ Stock Analysis page.